**Main Article**

Dr L A Vaira takes responsibility for the integrity of the content of the paper

Cite this article: Vaira LA et al. Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and prospective study. J Laryngol Otol 2020;134:703-709. https://doi.org/10.1017/S0022215120001826

Accepted: 27 July 2020

First published online: 12 August 2020

Key words: COVID-19; Ageusia; Anosmia; Gustatory Dysfunction; SARS-CoV-2; Coronavirus; Hypogeusia; Smell; Taste

Author for correspondence: Dr Luigi Angelo Vaira, Viale San Pietro 43/B, 07100 Sassari, Italy

E-mail: luigi.vaira@gmail.com
Fax: +39 079 229 002

© The Author(s), 2020. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Abstract**

**Background.** The long-term recovery rate of chemosensitive functions in coronavirus disease 2019 patients has not yet been determined.

**Method.** A multicentre prospective study on 138 coronavirus disease 2019 patients was conducted. Olfactory and gustatory functions were prospectively evaluated for 60 days.

**Results.** Within the first 4 days of coronavirus disease 2019, 84.8 per cent of patients had chemosensitive dysfunction that gradually improved over the observation period. The most significant increase in chemosensitive scores occurred in the first 10 days for taste and between 10 and 20 days for smell. At the end of the observation period (60 days after symptom onset), 7.2 per cent of the patients still had severe dysfunctions. The risk of developing a long-lasting disorder becomes significant at 10 days for taste (odds ratio = 40.2, 95 per cent confidence interval = 2.204–733.2, \( p = 0.013 \)) and 20 days for smell (odds ratio = 58.5, 95 per cent confidence interval = 3.278–1043.5, \( p = 0.005 \)).

**Conclusion.** Chemosensitive disturbances persisted in 7.2 per cent of patients 60 days after clinical onset. Specific therapies should be initiated in patients with severe olfactory and gustatory disturbances 20 days after disease onset.

**Introduction**

Chemosensitive dysfunction is now considered one of the most frequent symptoms in the early stages of coronavirus disease 2019 (Covid-19).111-11 Objective psychophysical evaluation is challenging because of logistical and safety problems. Consequently, as of 1 July 2020, only six retrospective psychophysical studies have been published,12-17 and only three of them investigate both olfactory and gustatory functions.12-14

In the absence of prospective studies, the long-term recovery rate of chemosensitive function has not yet been determined. Although many authors have reported complete recovery in most patients within a few weeks,3,7,8,10 psychophysical studies have found that around 25 per cent of patients evaluated 30 days after the clinical onset of Covid-19 have severe chemosensitive disorders (i.e. anosmia, ageusia, severe hyposmia or severe hypogeusia).12,13 Clearly, there is still potential for delayed recovery, but the consequence of such a frequent, persistent severe chemosensitive dysfunction, given the high incidence of infection, means that there will be a significant number of patients with potentially long-term morbidity.

In order to understand the longer-term recovery rate of chemosensitive functions, so as to aid the counselling of patients and guide if and when it is appropriate to start a specific therapy, we prospectively evaluated 138 Covid-19 patients with psychophysical tests in 3 Italian hospitals for a period of 60 days from clinical onset of the disease.

**Materials and methods**

This multicentre prospective study involved three Italian Covid-19 hospitals: University Hospital of Sassari, San Paolo Hospital in Milan, and Bellaria-Maggiore Hospital in
Bologna. The evaluation protocol was approved by an independent ethics committee (approval number: 378-2020-OSS-AUSLBO) and the subjects provided informed consent for participation in the study.

The study included only adult patients aged over 18 years. All patients were symptomatic and presented within 4 days of symptom onset. The patients had a diagnosis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection confirmed using reverse transcription polymerase chain reaction analysis of nasopharyngeal swabs. Patients with a history of previous trauma, surgery or radiotherapy in the oral and nasal cavities, allergic rhinitis or rhinosinusitis, or psychiatric or neurological diseases, were excluded from the study.

All patients underwent an evaluation protocol that included psychophysical tests to assess olfactory and gustatory functions every 10 days, for an observation period of 60 days. The first evaluation (baseline) was always performed within 4 days of clinical onset, as per the inclusion criterion. The subsequent assessment (observation time 1) took place 10 days after symptom onset (not baseline). The patient was then evaluated every 10 days for 60 days (observation time 2 to observation time 6).

The evaluation of home-quarantined patients was performed by means of patient self-administered olfactory and gustatory psychophysical tests.18 These tests, which have recently been validated for the evaluation of patients in home quarantine using common household odorants and flavours, can be executed remotely by the operator. The evaluation includes an ethyl-alcohol olfactory threshold assessment with nine solutions of decreasing concentration, and a gustatory and olfactory discriminatory function assessment involving seven groups of odorants and four flavoured solutions prepared by the patient.

Hospitalised patients were instead tested with the Connecticut Chemosensory Clinical Research Center orthonasal olfaction test,19 a widely used and validated test that includes a butanol threshold evaluation and an odour identification task. A validated discrimination test was carried out to assess taste function, investigating the discriminatory capability for four primary tastes.

The evaluation methodology and scoring system of the two olfactory and gustatory psychophysical tests have been previously described in detail.12,13,18 The two tests provide standardised olfactory and gustatory scores, on the same severity scale, that can be analysed together.

Statistical analysis was performed with SPSS 26.0 software (IBM, Armonk, New York, USA). Categorical variables are expressed in numerals and percentages of the total. Descriptive statistics for quantitative variables are given as the mean ± standard deviation. The Wilcoxon signed-rank test for paired data was performed to evaluate the statistical significance of changes in olfactory and gustatory scores during the observation period. Logistic regression analysis and Fisher’s exact tests were used to evaluate the significance of the correlations between persistent chemosensory disorders at day 60 and: scores obtained in the different observation times, age, sex, the need for hospitalisation and co-morbidities. The odds ratio was calculated for each variable examined. For the logistic regression analysis, patients were divided into two groups, based on the olfactory and gustatory scores obtained at each observation time: a ‘dysfunction group’ (anosmia or ageusia, or moderate to severe hyposmia or hypogeusia) and a ‘no dysfunction group’ (normal chemosensitve function, mild hyposmia and hypogeusia). The level of statistical significance was set at \( p < 0.05 \), with a 95 per cent confidence interval.

Results

A total of 150 Covid-19 patients in the involved hospitals who met the inclusion criteria were enrolled in the study. During the observation period, four patients required invasive ventilation and intensive care unit hospitalisation. In addition, eight patients were lost during follow up for reasons unrelated to health conditions. The data for the 138 patients who completed the evaluation protocol were considered for statistical analysis. General and clinical features of the patients are summarised in Table 1.

Within the first 4 days of Covid-19 symptom onset, 84.8 per cent of patients had chemosensitive dysfunction (Tables 2 and 3). Specifically, severe olfactory and gustatory disorders (i.e. anosmia or severe hyposmia, and ageusia or severe hypogeusia) affected 60.9 per cent and 40.6 per cent of patients, respectively (Figures 1 and 2). Progressive and statistically significant improvements in olfactory and gustatory scores were observed at every observation point. The most significant increase in gustatory scores occurred within the first 10 days (observation time 1); the most significant improvement in smell took place between 10 (observation time 1) and 20 days (observation time 2) after symptom onset (Tables 2 and 3). At the end of the observation period (observation time 6, 60 days after symptom onset), eight patients (5.8 per cent) still had moderate to severe olfactory dysfunction (Figure 1), while six patients (4.3 per cent) still had a significant taste disorder (Figure 2). Four patients had combined chemosensitive dysfunctions, four patients had isolated smell impairments and two patients had isolated taste disorders.

Any associations between age, gender, need for hospitalisation, cardiovascular and pulmonary co-morbidities, diabetes and obesity and the persistence of chemosensitive disorders at 60 days were assessed with logistic regression analysis (Table 4), but no significant relationships were found.

All patients with persistent chemosensitive disorders had severe dysfunction from the beginning of the observation period. However, at baseline (within 4 days of clinical onset), the risk was increased but not significant for both smell and taste. Following the different recovery curves (Figures 1 and 2), the risk of developing a long-lasting severe olfactory disorder, based on the presence of severe dysfunction at the time of

---

**Table 1. General and clinical characteristics of study population**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (n (%))</td>
<td></td>
</tr>
<tr>
<td>– Male</td>
<td>68 (49.3)</td>
</tr>
<tr>
<td>– Female</td>
<td>70 (50.7)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>– Mean (SD)</td>
<td>51.2 (8.8)</td>
</tr>
<tr>
<td>– IQR</td>
<td>46.7–58.0</td>
</tr>
<tr>
<td>In-patients (n (%))</td>
<td>32 (23.2)</td>
</tr>
<tr>
<td>Out-patients (n (%))</td>
<td>106 (76.8)</td>
</tr>
<tr>
<td>Co-morbidities (n (%))</td>
<td></td>
</tr>
<tr>
<td>– Cardiovascular disorder</td>
<td>37 (26.8)</td>
</tr>
<tr>
<td>– Pulmonary disorder</td>
<td>21 (15.2)</td>
</tr>
<tr>
<td>– Diabetes</td>
<td>15 (10.9)</td>
</tr>
<tr>
<td>– BMI &gt;30 kg/m²</td>
<td>40 (29)</td>
</tr>
</tbody>
</table>

SD = standard deviation; IQR = interquartile range; BMI = body mass index
observation, became significant at observation time 2 (20 days after symptom onset) (Table 5). As for taste, this risk was significant earlier, at observation time 1 (10 days after symptom onset) (Table 6).

**Discussion**

This objective and prospective study represents the first psychophysical evaluation of patients in the very early stages of Covid-19. We found no cases of deterioration in terms of the olfactory and gustatory scores from baseline (within 4 days of clinical onset) to observation time 1 (10 days after symptom onset). This finding confirms that chemosensitive disorders are most prevalent at the earliest stages of the disease.

Of the patients, 84.8 per cent had at least one chemosensitive disorder at baseline; this frequency is higher than that reported in some other psychophysical studies which evaluated patients at later stages of the disease. At the end of the observation period, patients presented with mild hyposmia or hypogeusia in 15.2 per cent and 3.6 per cent of cases, respectively. These frequencies are in line with those normally

---

**Table 2.** Chemosensitive evaluation results: olfactory scores*

<table>
<thead>
<tr>
<th>Observation time</th>
<th>Olfactory score (median (IQR))</th>
<th>Comparison</th>
<th>Correlation co-efficient</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline (T0)</td>
<td>45 (10–90)</td>
<td>T0 vs T1</td>
<td>0.920</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>10 days after symptom onset (T1)</td>
<td>50 (40–90)</td>
<td>T1 vs T2</td>
<td>0.846</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>20 days after symptom onset (T2)</td>
<td>80 (60–100)</td>
<td>T2 vs T3</td>
<td>0.971</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>30 days after symptom onset (T3)</td>
<td>80 (70–100)</td>
<td>T3 vs T4</td>
<td>0.957</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>40 days after symptom onset (T4)</td>
<td>90 (70–100)</td>
<td>T4 vs T5</td>
<td>0.922</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>50 days after symptom onset (T5)</td>
<td>100 (90–100)</td>
<td>T5 vs T6</td>
<td>0.975</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>60 days after symptom onset (T6)</td>
<td>100 (90–100)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Of the 138 patients, 22 (15.9 per cent) had isolated taste dysfunction, 69 (50 per cent) had combined dysfunction, 26 (18.8 per cent) had isolated olfactory dysfunction and 21 (15.2 per cent) had normal findings (no chemosensory disorder). IQR = interquartile range

**Table 3.** Chemosensitive evaluation results: gustatory scores*

<table>
<thead>
<tr>
<th>Observation time</th>
<th>Gustatory score (median (IQR))</th>
<th>Comparison</th>
<th>Correlation co-efficient</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline (T0)</td>
<td>2 (0–4)</td>
<td>T0 vs T1</td>
<td>0.666</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>10 days after symptom onset (T1)</td>
<td>3 (2–4)</td>
<td>T1 vs T2</td>
<td>0.831</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>20 days after symptom onset (T2)</td>
<td>4 (3–4)</td>
<td>T2 vs T3</td>
<td>0.919</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>30 days after symptom onset (T3)</td>
<td>4 (3–4)</td>
<td>T3 vs T4</td>
<td>0.893</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>40 days after symptom onset (T4)</td>
<td>4 (4–4)</td>
<td>T4 vs T5</td>
<td>0.933</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>50 days after symptom onset (T5)</td>
<td>4 (4–4)</td>
<td>T5 vs T6</td>
<td>0.975</td>
<td>0.025</td>
</tr>
<tr>
<td>60 days after symptom onset (T6)</td>
<td>4 (4–4)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Of the 138 patients, 22 (15.9 per cent) had isolated taste dysfunction, 69 (50 per cent) had combined dysfunction, 26 (18.8 per cent) had isolated olfactory dysfunction and 21 (15.2 per cent) had normal findings (no chemosensory disorder). IQR = interquartile range

---

**Fig. 1.** Olfactory clinical diagnosis and trend score during the observation period.

**Fig. 2.** Gustatory clinical diagnosis and trend score during the observation period.
found in the healthy population. All these cases of mild dysfunction had a more severe disorder at baseline. This finding corroborates the reliability of the prevalence of chemosensitive disturbance at baseline. This parameter could be overestimated if the psychophysical tests were performed only in the later stages of disease, because of potential bias introduced by including patients unaware of having previous mild hyposmia or hypogeusia. Of course, in the absence of testing prior to

Table 4. Logistic regression and crosstab analysis for anamnestic and clinical features

<table>
<thead>
<tr>
<th>Variables compared</th>
<th>Normal function at T6 (n (%))</th>
<th>Residual dysfunction at T6 (n (%))</th>
<th>OR</th>
<th>95% CI for OR</th>
<th>Lower limit</th>
<th>Upper limit</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV = age; DV = persistent chemosensitive disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Age: &lt;50 years</td>
<td>49 (89.1)</td>
<td>6 (10.9)</td>
<td>2.42</td>
<td>0.649</td>
<td>9.003</td>
<td>0.188</td>
<td></td>
</tr>
<tr>
<td>– Age: ≥50 years</td>
<td>79 (95.2)</td>
<td>4 (4.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV = gender; DV = persistent chemosensitive disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Gender: male</td>
<td>64 (89.2)</td>
<td>4 (10.8)</td>
<td>0.667</td>
<td>0.179</td>
<td>2.475</td>
<td>0.545</td>
<td></td>
</tr>
<tr>
<td>– Gender: female</td>
<td>64 (100)</td>
<td>6 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV = hospitalisation; DV = persistent chemosensitive disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Hospitalisation: in-patients</td>
<td>29 (90.6)</td>
<td>3 (9.4)</td>
<td>1.463</td>
<td>0.357</td>
<td>6.109</td>
<td>0.598</td>
<td></td>
</tr>
<tr>
<td>– Hospitalisation: out-patients</td>
<td>99 (93.4)</td>
<td>7 (6.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV = co-morbidities; DV = persistent chemosensitive disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Co-morbidity: cardiovascular disorder</td>
<td>1.184</td>
<td>0.289</td>
<td>4.845</td>
<td>0.813</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Co-morbidity: pulmonary disorder</td>
<td>0.600</td>
<td>0.072</td>
<td>5</td>
<td>0.637</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Co-morbidity: diabetes</td>
<td>2.211</td>
<td>0.424</td>
<td>11.54</td>
<td>0.364</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Co-morbidity: BMI &gt;30 kg/m²</td>
<td>2.657</td>
<td>0.725</td>
<td>9.741</td>
<td>0.140</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

T6 = observation time 6 (60 days after symptom onset, at the end of the observation period); OR = odds ratio; CI = confidence interval; IV = independent variable; DV = dependant variable

Table 5. Olfactory logistic regression and crosstab analysis results

<table>
<thead>
<tr>
<th>Observation period</th>
<th>Normal function at T6 (n (%))</th>
<th>Residual dysfunction at T6 (n (%))</th>
<th>OR</th>
<th>95% CI for OR</th>
<th>Lower limit</th>
<th>Upper limit</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline (T0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>78 (90.7)</td>
<td>8 (9.3)</td>
<td>11.36</td>
<td>0.642</td>
<td>201.1</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>52 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 days after symptom onset (T1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>66 (89.2)</td>
<td>8 (10.8)</td>
<td>16.48</td>
<td>0.932</td>
<td>291.6</td>
<td>0.056</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>64 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 days after symptom onset (T2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>29 (78.4)</td>
<td>8 (21.6)</td>
<td>58.49</td>
<td>3.278</td>
<td>1043.5</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>101 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 days after symptom onset (T3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>26 (76.5)</td>
<td>8 (23.5)</td>
<td>67.03</td>
<td>3.748</td>
<td>1198.8</td>
<td>0.004</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>104 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 days after symptom onset (T4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>15 (65.2)</td>
<td>8 (34.8)</td>
<td>126.6</td>
<td>6.963</td>
<td>2304.7</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>115 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 days after symptom onset (T5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>7 (46.7)</td>
<td>8 (53.3)</td>
<td>279.9</td>
<td>14.71</td>
<td>5326.6</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>123 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Odds ratios quantify the likelihood of presenting with a residual olfactory dysfunction at the observation time considered. OR = odds ratio; CI = confidence interval
development of Covid-19, we cannot be sure that the mild hyposmia does represent incomplete recovery, but it is likely that at least some cases reflect pre-existing dysfunction.

We concur with the findings of Moein et al., which suggest that self-reported olfactory or gustatory loss underestimates the frequency of chemosensitive disorders. In our series, at baseline, 10.3 per cent of patients who were found to have a chemosensitive disorder on objective testing had self-reported normal function. In the same way, interview-based studies are not able to fully evaluate functional recovery. A significant number of patients with severe chemosensitive dysfunction at baseline self-reported complete recovery, even though mild or moderate hyposmia or hypogeusia persisted according to the objective tests.

Generally, gustatory function has a rapid recovery. Compared to baseline, the number of patients with moderate to severe dysfunction is reduced by 60.7 per cent at 10 days (observation time 1) and is reduced by 80.9 per cent at 20 days (observation time 2) after the clinical onset of disease (Figure 2). Moderate to severe gustatory disorder was still present in six patients (4.3 per cent) at the end of the observation period (observation time 6, 60 days after symptom onset). The recovery of olfactory function was slower, but most notable between observation time 1 and observation time 2 (Table 2). The number of patients with moderate to severe dysfunction at baseline decreased by 13.8 per cent at observation time 1 and decreased by 54 per cent at observation time 2. One month after the onset of symptoms, 39.1 per cent of these patients continued to present with severe or moderate olfactory dysfunction (Figure 1). At the end of the observation period, eight patients (5.8 per cent) presented with residual moderate to severe olfactory disturbance.

The continued improvement of chemosensory function during the whole observation period suggests a pathogenetic mechanism linked to interference of the virus on the taste and smell receptors or to local inflammatory phenomena, rather than central nervous system invasion and permanent neuronal damage. We did not find any predictive factors for the persistence of chemosensitive disorders (Table 3), but our sample may be too small. Larger studies will be needed to determine whether there are predisposing factors for developing long-lasting severe chemosensitive disorders.

Only 10 patients (7.2 per cent) still had severe olfactory or gustatory dysfunction 60 days after symptom onset, which is encouraging news for patients in the early stages of Covid-19, as the majority are likely to recover. However, given the high prevalence of infection in the general population, Covid-19 will still result in a large number of patients with long-term morbidity.

Regarding treatment initiation, it is important to consider both the likelihood of spontaneous recovery and the potential risks of treatments. Our data suggest that the greatest rate of recovery for olfactory disorders occurs between 10 and 20 days, by which time only 20 per cent of patients have severe persisting loss. All patients with moderate hyposmia at 20 days improved further by 60 days. Thus, specific therapy for

---

**Table 6. Gustatory logistic regression and crosstab analysis results**

<table>
<thead>
<tr>
<th>Observation period</th>
<th>Normal function at T6 (n (%))</th>
<th>Residual dysfunction at T6 (n (%))</th>
<th>OR</th>
<th>95% CI for OR</th>
<th>Lower limit</th>
<th>Upper limit</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline (T0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>83 (93.3)</td>
<td>6 (6.7)</td>
<td>7.706</td>
<td>0.425</td>
<td>139.7</td>
<td>0.167</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>49 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 days after symptom onset (T1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>32 (84.2)</td>
<td>6 (15.8)</td>
<td>40.2</td>
<td>2.204</td>
<td>733.2</td>
<td>0.013</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>100 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 days after symptom onset (T2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>11 (64.7)</td>
<td>6 (35.3)</td>
<td>137.3</td>
<td>7.266</td>
<td>2596.4</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>121 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 days after symptom onset (T3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>4 (40)</td>
<td>6 (60)</td>
<td>371.2</td>
<td>18.0</td>
<td>7645</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>128 (100)</td>
<td>0 (80)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 days after symptom onset (T4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>1 (14.3)</td>
<td>6 (85.7)</td>
<td>1139.6</td>
<td>42.197</td>
<td>30780</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>131 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 days after symptom onset (T5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Dysfunction group</td>
<td>0 (0)</td>
<td>6 (100)</td>
<td>3445.0</td>
<td>63.20</td>
<td>187771</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>– No dysfunction group</td>
<td>132 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Odds ratios quantify the likelihood of presenting with a residual gustatory dysfunction at the observation time considered. OR = odds ratio; CI = confidence interval.
severe olfactory disorders should be considered if persistent for more than 20 days (observation time 2: odds ratio = 58.5, CI = 3.278–1043.5, \( p = 0.005 \)) (Table 4).

There is a paucity of high-quality evidence regarding potential treatments for post-viral morbidity, and no studies have exclusively investigated olfactory loss following Covid-19 infection. The majority of trials include very small numbers, most lack blinding, randomisation and a control arm, and rates of improvement are usually no greater than reported rates of spontaneous improvement. It is also difficult to compare the current cohort of patients to those seen previously with post-viral loss, as the focus on anosmia during the pandemic has allowed us the unique opportunity to study patients with post-Covid-19 loss at a much earlier stage. However, we can make some recommendations on treatment based on previous studies.

Studies of olfactory training suggest small to moderate benefits in terms of both identification and discrimination, but not thresholds compared to control groups. Although the effect size may be small, all patients with severe loss should be encouraged to undertake olfactory training, as the risk of harm is minimal.

Oral steroids, but not topical steroids, were shown to improve olfactory function in a group of patients including post-viral anosmia cases. However, there are concerns regarding the use of systemic steroids in cases with or at risk of severe acute respiratory Covid-19. For instance, a systematic review of usage in influenza cases suggests possible harm.

Furthermore, delayed viral clearance has been previously demonstrated in Middle East respiratory syndrome. However, if decisions regarding usage are delayed until day 20, the risks of developing long-term morbidity will be significantly reduced.

Alpha-lipoic acid has been shown to improve the results of objective tests of olfactory function in an uncontrolled study, but its use can be associated with neurological side effects, including headache, dizziness and confusion, which may be difficult to interpret alongside Covid-19 manifestations. Omega-3 supplementation was found to be protective against olfactory loss during the recovery period after skull base surgery and therefore may have potential in aiding recovery after post-viral olfactory loss, although this has not been formally tested in Covid-19 patients. Intranasal vitamin A added to olfactory training resulted in greater rates of improvement compared with olfactory training alone, but it is locally irritant to the nose.

Medical treatments specifically aimed at hypoguesia are even more limited and no specific recommendations can be made. The differences between the chemosensitive scores at observation time 5 (50 days after symptom onset) and observation time 6 (60 days after symptom onset) were significant. Hence, in some cases, the recovery process is still ongoing 60 days after clinical onset of the disease. We will continue to follow these patients to understand whether Covid-19 is capable of causing permanent olfactory or gustatory disturbances. Histological analysis of samples taken from these patients may be useful in determining the pathogenesis of these disorders.

**Conclusion**

Olfactory and gustatory disturbances in Covid-19 patients are frequent and common in the early stages of the disease. In most cases, they resolve completely within 30 days. Moderate to severe olfactory or gustatory disturbance persisted in 7.2 per cent of patients 60 days after clinical onset of the disease. In order to avoid long-term morbidity, specific therapies should be initiated in patients with moderate to severe olfactory disturbance 20 days after disease onset.

**Competing interests**

None declared

**References**

11. Lechien JR, Hopkins C, Saussée S. Sniffing out the evidence: it’s now time for public health bodies recognize the link between COVID-19 and smell and taste disturbance. Rhinology 2020. Epub 2020 Apr 30
30 Hummel T, Heilmann S, Hutenbrink KB. Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract. Laryngoscope 2002;112:2076–80